摘要在宫颈癌的临床研究中，放化疗联合免疫治疗取得了一定成果，程序性死亡受体1/程序性死亡受体配体1抑制剂在多项临床试验中亦展现出积极的结果。人乳头状瘤病毒多肽疫苗、DNA疫苗、肿瘤浸润淋巴细胞疗法和双特异性抗体等新型免疫疗法也在复发或转移性宫颈癌治疗中有所应用，展现出显著的抗肿瘤活性、重塑免疫微环境、适配个体化治疗及与多模式联合增效等潜力。深入探讨联合治疗方案的协同机制及多种疗法在宫颈癌治疗中的应用和发展限制因素，可为进一步优化宫颈癌的治疗策略提供思路。

abstractsIn clinical studies of cervical cancer, the combination of radiotherapy, chemotherapy, and immunotherapy has yielded certain results. Programmed death-1/programmed death-ligand 1 inhibitors have also demonstrated positive results in multiple clinical trials. Novel immunotherapies such as human papillomavirus peptide vaccines, DNA vaccines, tumor-infiltrating lymphocyte therapy, and bispecific antibodies have been applied in the treatment of recurrent or metastatic cervical cancer, demonstrating significant anti-tumor activity, the potential to reshape the immune microenvironment, adaptability to personalized treatment, and synergistic effects when combined with multi-modal therapies. A deeper exploration of the synergistic mechanisms of combined therapy regimens and the application and development limitations of various therapies in cervical cancer treatment can provide insights for further optimizing treatment strategies for cervical cancer.